drugset / Trial / NCT00420277

Phase III Study of Hemospan® for Treating Hypotension in Hip Arthroplasty

NCT00420277

Phase 3 Completed 462 enrolled Sangart
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine whether Hemospan is superior to Voluven for treatment of hypotensive episodes during the perioperative period (from induction of spinal anesthesia until 6 hours after skin closure), and for reducing the incidence of operative and postoperative complications including organ dysfunction and failure until follow-up at one month following surgery. An independent Data Safety Monitoring Board (DSMB) will periodically evaluate the safety data collected during this trial

Timeline

Start
2007-02
Primary completion
2008-03
Completion
2008-04

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Hemospan Protein / enzyme biologic 250 ml
Comparator hydroxyethyl starch Other / unclassified 250 ml